Jump to a section
Buy sermorelin: 10 mg vial or 6 mg pen
The vial contains 10 mg of powder. The pen contains 6 mg in 3 mL of prepared liquid. Sermorelin is the only active peptide in each. The pen removes the mixing step; the vial contains more peptide. [1]
Online ordering is not available yet.
Sermorelin 10 mg vial
Single-ingredient freeze-dried powder. Final concentration depends on the prepared volume.
- Contents
- 10 mg sermorelin
- Format
- White to off-white powder
- Preparation
- Reconstitution required
- Sealed storage
- −20°C (−4°F) · dry and dark
Powder lot PL-2609-098. Reported purity and the printed peak-area calculation disagree; see the COA note below.
Sermorelin 6 mg prefilled pen
3 mL of prepared solution at 2 mg/mL. No powder-mixing step.
- Cartridge
- 3 mL · 2 mg/mL
- Solution
- Water + 0.9% benzyl alcohol
- Preparation
- Already mixed
- Storage
- 2–8°C (36–46°F) · do not freeze
Powder-lot reference only. The report does not test the finished pen or establish its lot linkage.
Research-labelled products. Drawings show the formats; they are not product photographs.
| Product detail | 10 mg vial | 6 mg pen |
|---|---|---|
| Total sermorelin | 10,000 mcg | 6,000 mcg |
| Supplied form | Freeze-dried powder | Prepared liquid |
| Concentration | Depends on final volume | 2 mg/mL |
| Mixing | Required | No water added |
| Sealed storage | −20°C, dry and dark | 2–8°C; do not freeze |
| Redacted COA | Sampled powder lot | Powder-lot reference only |
A milligram comparison measures product content. It does not establish how well either format works or how much to use. For those questions, read the sermorelin benefits and dosage and duration articles.
Sermorelin 10 mg powder vial
One vial contains a labelled 10 mg, equal to 10,000 mcg. The white to off-white powder sits in a sealed glass vial with a rubber stopper and aluminium crimp. No liquid concentration exists until the powder has been prepared to a known final volume. [1]
10 mg
Sermorelin in one powder vial.
5 mg/mL
Concentration at a final mixed volume of 2 mL.
0.06 mL
Six U-100 syringe units at that concentration.
These are conversion examples, not a selected treatment dose. At a final volume of 3 mL, the same vial would contain approximately 3.33 mg/mL. A 300 mcg target would then occupy 0.09 mL, or nine U-100 units. Adding more liquid changes the volume needed for a target amount; it does not add peptide.
The supplied handling instructions specify slow addition against the vial wall without shaking. They do not establish a validated preparation liquid or an expiry after mixing. The reconstitution section separates those missing preparation details from the concentration calculator.
Sermorelin 6 mg pen: 3 mL at 2 mg/mL
The pen contains 60% of the sermorelin in one 10 mg vial. Its 2 mg/mL concentration is already set. The solution contains water and 0.9% benzyl alcohol; no water is added to the cartridge. It should be clear and colourless to faint yellow. [1]
The same concentration can appear as 0.2% w/v: 0.2 g per 100 mL equals 2 mg/mL. Multiplying 2 mg/mL by the 3 mL fill gives 6 mg total. Reading “2 mg/mL” as “2 mg per pen” would undercount the contents by three.
300 mcg equals 0.15 mL
At 2 mg/mL: 0.3 mg ÷ 2 mg/mL = 0.15 mL. The pen's marked-unit and click calibration are unconfirmed. A liquid volume cannot be converted into a dial setting without that device specification.
A U-100 syringe scale is a separate measurement system. Its markings do not establish the output of this pen. A chart from another peptide pen also cannot confirm this cartridge's mechanical steps or delivery accuracy.
Each 1 mL contains 2,000 mcg; 0.1 mL contains 200 mcg and 0.25 mL contains 500 mcg. Compared with a 10 mg vial prepared to 2 mL, this pen's liquid is 40% as concentrated. The same peptide amount therefore occupies 2.5 times as much liquid.
Sermorelin alone, with no added peptide
Neither product is a sermorelin–ipamorelin blend. Their active peptide is sermorelin, also called GHRH(1–29)-NH₂ or GRF(1–29). The redacted certificate identifies a 29-amino-acid sequence with a C-terminal amide and CAS number 86168-78-7. [2]
The product name, peptide amount and ingredient list should agree. A blend labelled “10 mg total” can contain less than 10 mg of sermorelin because another ingredient shares that total. These two products list 10 mg and 6 mg of sermorelin respectively, without another active peptide.
The exact salt counterion is not identified for the supplied lot. A generic reference to acetate or TFA in handling information does not resolve which salt is present. The certificate's molecular formula and theoretical peptide mass identify the named peptide, not a separate quantitative counterion result.
Vial and pen quantities at the same target amount
At 300 mcg per calculated portion, a 10 mg vial gives 33⅓ portions and a 6 mg pen gives 20. These totals exclude priming, remaining liquid, transfer losses and discard limits. They describe content arithmetic, not a treatment course or usable shelf life.
| Target amount | 10 mg vial | 6 mg pen |
|---|---|---|
| 200 mcg | 50 portions | 30 portions |
| 300 mcg | 33⅓ portions | 20 portions |
| 500 mcg | 20 portions | 12 portions |
The fractional vial result means 33 complete 300 mcg portions plus a theoretical 100 mcg remainder. It does not mean a device can accurately deliver every remainder. The pen's unknown calibration remains a separate constraint even when the division gives a whole number.
Five pens and three vials each contain a labelled 30 mg. The packages differ in preparation, concentration and losses. Total milligrams alone cannot establish an equivalent ready-to-use supply.
Compare cost per milligram
Divide the vial price by 10 and the pen price by 6. Those calculations give price per labelled milligram. For equal cost per milligram, the pen would cost 60% of the vial price. At a higher price ratio, the pen costs more per milligram.
Prepared convenience can still affect the comparison. Mixing supplies, measurement equipment, priming and discarded remainder add costs beyond the peptide total. No retail price, stock promise or checkout destination is currently supplied for this site, so ordering controls remain unavailable.
Frozen powder, refrigerated pen
−20°C / −4°F
Keep dry and protected from light. The frozen-storage specification applies to the sealed powder.
2–8°C / 36–46°F
Keep capped in its original carton, away from light. Do not freeze. Discard if frozen, cloudy or discoloured.
Prepared vial solution also requires refrigerated storage under its preparation method. Neither the supplied vial information nor the pen specification establishes a universal 28-day opened life. The presence of benzyl alcohol does not supply that missing stability period. [1]
The powder lot's retest/expiry date is 18 September 2028 under its specified storage conditions. That date does not become the expiry of a mixed vial or opened pen. [2]
A storage excursion also needs product-specific handling information. The supplied documents do not quantify a safe number of hours unrefrigerated for the pen, or show that refreezing restores a compromised product. Temperature limits for the dry powder cannot be used for its already prepared counterpart.
Redacted sermorelin certificate of analysis
Sermorelin — powder lot PL-2609-098
Two sampled powder vials from lot PL-2609-098; no finished-pen testing or lot linkage. The report states 99.63%, but its printed peak areas calculate to 99.48%. The analytical data is unchanged in the redacted copy.
Open redacted COACertificate PL-26-00098 covers two powder vials sampled from lot PL-2609-098, a lot of 250 units. It records a mass-spectrometry identity of 3358.1 Da, 1.8% water, 0.05 EU/mg endotoxin and no growth after 14 days in the sterility test. [2]
Purity figures need clarification
The report states 99.63% RP-HPLC area purity. Its printed peak areas give 4,284,090 ÷ 4,306,450 × 100 = 99.48%, and the listed percentages add up to 100.15%. A corrected table or laboratory explanation is needed. The analytical data is unchanged in the redacted copy.
The calculated 99.48% is a check of the printed table, not a new laboratory assay. It cannot establish which entry needs correction. Both the stated result and the discrepancy remain visible so the certificate is not presented as an independently reconciled purity result.
The report lists the largest additional peak as 0.19% at 7.12 minutes, identified as a des-Arg29 fragment. HPLC area percentages describe chromatogram peaks; they do not independently measure how many milligrams are in each vial. No separate quantitative fill-content assay is supplied.
The identity result differs by 0.2 Da from the stated theoretical mass of 3357.9 Da. That supports identification of the tested peptide under the report's method; it does not resolve the separate peak-area discrepancy or measure pen concentration.
This is an in-house report with no outside laboratory attachment. It tests sampled powder vials. Its presence beside the pen does not establish finished-cartridge content, sterility, stability or a verified link between the pen batch and this powder lot.
Questions & answers.
Does the sermorelin pen contain 2 mg or 6 mg?
6 mg total. The concentration is 2 mg/mL and the cartridge contains 3 mL. Multiplying those figures gives the full pen amount.
Is one sermorelin pen equivalent to one 10 mg vial?
No. The pen has 6 mg, or 60% of the vial’s labelled content. Both contain sermorelin alone, but their preparation and concentration differ.
How many pen clicks equal 300 mcg?
The click setting is unconfirmed. At 2 mg/mL, 300 mcg occupies 0.15 mL. Product-specific device calibration is needed to translate that volume into dial marks or clicks.
Does the COA verify the finished pen?
No. It covers two sampled powder vials from lot PL-2609-098. Finished-pen content, sterility, stability and batch linkage are not established.
Is 99.63% purity independently confirmed?
It is the in-house report’s stated result. The printed peak areas calculate to 99.48%, so the report needs clarification. Neither percentage is a separate assay of the 10 mg vial fill.